Načítá se...
Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain
Resistance to the BRAF inhibitor vemurafenib poses a significant problem for the treatment of BRAFV600E-positive melanomas. It is therefore critical to prospectively identify all vemurafenib-resistance mechanisms prior to their emergence in the clinic. The vemurafenib-resistance mechanisms described...
Uloženo v:
| Vydáno v: | Pigment Cell Melanoma Res |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4260813/ https://ncbi.nlm.nih.gov/pubmed/24112705 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12171 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|